IFN-γ and IL-2, secreted by CD4 + Th1 cells, trigger the activation of DCs and enhance the cross-presentation of tumor-associated antigens (TAAs), thereby priming anti-tumor CD8 + T cells and supporting their differentiation into mature CD8 + cytotoxic T lymphocytes (CTLs). The gene discussed is CD8A; the disease is neoplasm.